Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer GlobeNewswire November 10, 2025 LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic […]

Matador Technologies Inc. Announces Closing of Convertible Note Facility to Expand Bitcoin Holdings GlobeNewswire November 10, 2025 TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (TSXV:MATA, OTCQB:MATAF, FSE:IU3) (“Matador” or the “Company“), the Bitcoin Ecosystem Company, is pleased to announce that it has closed the first tranche (the “Initial Closing“) of its previously

NEW YORK, NY / ACCESS Newswire / November 10, 2025 / If you suffered a loss on your WPP plc (NYSE:WPP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/wpp-plc-lawsuit-submission-form?prid=176407&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

(NasdaqGM:VERA), BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit GlobeNewswire November 10, 2025 BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will

NEW YORK, NY / ACCESS Newswire / November 10, 2025 / If you suffered a loss on your Avantor, Inc. (NYSE:AVTR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/avantor-inc-lawsuit-submission-form?prid=176406&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / November 10, 2025 / If you suffered a loss on your RCI Hospitality Holdings, Inc. (NASDAQ:RICK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rci-hospitality-holdings-inc-lawsuit-submission-form?prid=176414&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

(NasdaqGM:PRE),(NYSE:EXOD),(HKSE:2228),(HKSE:1709), Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 – $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics

(ASX – Trade24:ATH.AX),(NASDAQ:ATHE), – Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia and SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology

(NASDAQ:DYAI), JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) — ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS' CRISPR/Cas9 patent portfolio, enhancing Dyadic's